Stability-based Ligand Screening Services
Biologics provide several advantages over small molecule therapy for several disease areas, including improved pharmacokinetics and target selectivity. In order to successfully commercialize a protein medication, a number of crucial characteristics must be tuned. Protein-based therapeutics require sophisticated production procedures and commercialization methods. Complex phases in the development and production of drugs might subject a biological to several kinds of environmental stress. The best chance for these medications to survive the challenging process of drug development is to have a sturdy candidate that can withstand these stressors in the most optimal solution condition to ensure optimum stability. Creative Biolabs can offer a wide of stability-based assay for GPCR ligand screening.
Stability-based Ligand Screening Services in Creative Biolabs
- GPCR Ligand Screening Services Using DSC
One of the basic biophysical methods for comprehending the conformational stability of a protein medication down to the domain level is DSC. Formulation scientists have used it extensively to screen biologics for stability in the presence of various excipients and additives. However, DSC investigations could need lengthy run durations and as much as a few micrograms of protein, which might make using DSC in the early stages of drug screening less feasible. Furthermore, handling DSC at a high throughput might be difficult and labor-intensive when it comes to actual data analysis.
- GPCR Ligand Screening Services Using DLS
Another technique for tracking size variation during developability screening is DLS. When a laser source is used to spotlight particles in a solution, DLS uses the time variation in the intensity of the scattered light from those particles to extract information about the concentration and size of those particles. The following are some of this method's benefits: It can handle high-throughput formats, needs little material, and is quick and non-destructive. Unfortunately, the resolution of this method is inadequate, and it can't provide precise quantitative information about particle concentrations (counts). With regard to particle material in the submicron/subvisible size range, this scenario is very concerning. As such, the most effective application of DLS is as a technique for quickly and qualitatively differentiating drug candidates or formulations based on how they aggregate.
- GPCR Ligand Screening Services Using DSF
Existing DSF instruments on the market use thermal ramping or scanning, or isothermal or both, to detect fluorescence both internally and outside. In certain instances, these instruments additionally offer concurrent light scattering/back reflection information, which could be helpful in determining which domain unfolding starts the aggregation. The aggregation dynamics of the whole molecule in a given buffer can be used to more accurately rank protein drug and drug formulation options. Nevertheless, it is evident that the unfolding of the first domain is what starts the molecule's aggregation in the screening buffer when DSC thermograms are superimposed over static light scattering data from DSF. However, the molecule's aggregation dynamics alter in the ideal formulation buffer, shifting aggregation to higher temperatures. As a result, one can comprehend both domain instability and its effect on aggregation by combining light scattering and fluorescence detection.
In the process of developing protein drugs, evaluating the developability of biologics can be extremely helpful since it can cut down on the time and money needed to solve issues that arise from protein drug candidates with subpar physicochemical characteristics. By utilizing new emerging analytical technologies in well-designed ways, we will be able to improve the biopharmaceutical business with better, faster, more affordable, and predictive processes for generating biologics. Please contact us for more information.
